Mayo Clinic, Department of Neurology, USA; Boston Children's Hospital, Department of Neurology, USA.
Mayo Clinic, Division of Biomedical Statistics and Informatics, USA.
Sleep Med. 2018 Mar;43:14-18. doi: 10.1016/j.sleep.2017.11.1125. Epub 2017 Nov 21.
To assess comorbidities in a community-based cohort of narcolepsy.
A 2000-2014 community-based narcolepsy cohort was identified in Olmsted County, Minnesota. Records were reviewed by a certified sleep specialist for accuracy of diagnosis, and comorbidities were extracted and analyzed. Comorbidities in narcolepsy subjects, both at diagnosis and upon follow-up, were compared with those in unaffected and age- and sex-matched cohort using conditional logistic regression.
At diagnosis, there was increased association of narcolepsy with anxiety (OR 4.56, 95% CI 1.99-10.44), thyroid disease (3.07, 1.19-7.90), hypertension (2.69, 1.22-5.93), and hyperlipidemia (2.49, 1.05-5.92). At the end of the prolonged observation period of 9.9 years (SD 7.27 years), there was increased association of narcolepsy with peripheral neuropathy (11.21, 1.16-108.11), non-migrainous headache (6.00, 1.73-20.83), glucose intolerance (2.39, 1.05-5.45), and automobile-related trauma (2.43, 1.08-5.45). Persistently increased both at diagnosis and after a prolonged observation period were associations of narcolepsy with obstructive sleep apnea (OSA) (69.25, 9.26-517.99 decreasing to 13.55, 5.08-36.14), chronic low back pain (5.46, 2.46-12.11 to 2.58, 1.39-4.77), depression (4.88, 2.45-9.73 to 3.79, 2.12-6.79), psychiatric disorders in general (4.73, 2.49-9.01 to 3.40, 1.94-5.98), endocrinopathies (4.15, 1.81-9.56 to 2.45, 1.33-4.49), and obesity (2.27, 1.13-4.56 to 2.07, 1.15-3.7).
In this community-based study of narcolepsy comorbidities, both at diagnosis and after prolonged follow-up, persistent comorbidities were revealed, including OSA, chronic low back pain, psychiatric disorders in general, endocrinopathies, and obesity. The comprehensive management of narcolepsy requires monitoring for and managing these important associated health conditions.
评估嗜睡症患者的合并症。
在明尼苏达州奥姆斯特德县确定了一个基于社区的嗜睡症队列。由一位经过认证的睡眠专家审查记录,以确保诊断的准确性,并提取和分析合并症。使用条件逻辑回归比较嗜睡症患者在诊断时和随访时的合并症与未受影响且年龄和性别匹配的队列的合并症。
在诊断时,嗜睡症与焦虑症(OR 4.56,95%CI 1.99-10.44)、甲状腺疾病(3.07,1.19-7.90)、高血压(2.69,1.22-5.93)和高脂血症(2.49,1.05-5.92)的关联增加。在 9.9 年(SD 7.27 年)的延长观察期结束时,嗜睡症与周围神经病(11.21,1.16-108.11)、非偏头痛性头痛(6.00,1.73-20.83)、葡萄糖耐量异常(2.39,1.05-5.45)和汽车相关创伤(2.43,1.08-5.45)的关联增加。在诊断时和延长观察期后均持续增加的是嗜睡症与阻塞性睡眠呼吸暂停(OSA)(69.25,9.26-517.99 减少至 13.55,5.08-36.14)、慢性下背痛(5.46,2.46-12.11 至 2.58,1.39-4.77)、抑郁症(4.88,2.45-9.73 至 3.79,2.12-6.79)、一般精神障碍(4.73,2.49-9.01 至 3.40,1.94-5.98)、内分泌疾病(4.15,1.81-9.56 至 2.45,1.33-4.49)和肥胖症(2.27,1.13-4.56 至 2.07,1.15-3.7)的关联。
在这项基于社区的嗜睡症合并症研究中,无论是在诊断时还是在延长随访后,都揭示了持续存在的合并症,包括 OSA、慢性下背痛、一般精神障碍、内分泌疾病和肥胖症。嗜睡症的综合管理需要监测和管理这些重要的相关健康状况。